Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06305637 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.
A Phase 1 study of Tinea Versicolor, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 430
- Enrollment target
- 1
- Study location
NCT06305637: Completed Phase 1 study of Tinea Versicolor, sponsored by Sun Pharmaceutical Industries.
NCT06305637 is a Phase 1 study of Tinea Versicolor that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 430 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (617% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06305637, a Phase 1 study of Tinea Versicolor, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 430 participants
- Enrollment target
- 1
- Study location
Study Summary
To demonstrate the efficacy, therapeutic equivalence and safety of Ketoconazole Shampoo, 2% (Taro Pharmaceuticals U.S.A., Inc.) and Ketoconazole 2% Shampoo (Reference Standard) in the treatment of tinea versicolor.
Primary Outcome
Proportion of subjects with treatment success/cure
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ketoconazole Shampoo, 2%
- DRUG Ketoconazole Shampoo, 2% (Reference Standard)
Study Locations (1)
New York
- Taro - Hawthorne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2024-02-10 |
| Phase | Phase 1 |
What the finished NCT06305637 record still lists
NCT06305637 is an interventional study that assigns participants to a tested intervention. The registered 430 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (617% higher).
The record links to 1 condition, with Tinea Versicolor appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06305637 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06305637 about?
NCT06305637 is a clinical study titled "A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.". To demonstrate the efficacy, therapeutic equivalence and safety of Ketoconazole Shampoo, 2% (Taro Pharmaceuticals U.S.A., Inc.) and Ketoconazole 2% Shampoo (Reference Standard) in the treatment of tinea versicolor.
What is the current status of trial NCT06305637?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 430 participants. The study started on 2023-12-04. Estimated completion is 2024-02-10.
What conditions does trial NCT06305637 study?
This clinical trial studies the following conditions: Tinea Versicolor.
What interventions are being tested in trial NCT06305637?
The interventions under investigation include: Placebo (DRUG), Ketoconazole Shampoo, 2% (DRUG), Ketoconazole Shampoo, 2% (Reference Standard) (DRUG).
Who is sponsoring clinical trial NCT06305637?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06305637 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06305637's enrollment target sits among peer trials
430 63rd of 2000 higher than 1,937 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
- NCT05844891 · 430 participants · NA
Telehealth-Enhanced Asthma Care for Home After the Emergency Room
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI